Christine Ring Sells 5,760 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $21.43, for a total value of $123,436.80. Following the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at $527,006.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Christine Ring also recently made the following trade(s):

• On Monday, July 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.81, for a total transaction of $119,865.60.
• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total value of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.00, for a total transaction of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total transaction of $27,147.96.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $20.78 on Friday. The stock has a market cap of $1.02 billion, a PE ratio of -7.12 and a beta of 2.22. The stock’s fifty day moving average is $19.32 and its two-hundred day moving average is $14.88. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $24.38.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The business had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on NRIX. Stifel Nicolaus reiterated a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, May 15th. Barclays upped their price objective on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, July 15th. JPMorgan Chase & Co. upped their target price on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. Finally, Stephens began coverage on Nurix Therapeutics in a report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 target price for the company. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Institutional Trading of Nurix Therapeutics

Several institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its position in shares of Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Nurix Therapeutics during the fourth quarter worth about $59,000. EntryPoint Capital LLC acquired a new stake in shares of Nurix Therapeutics during the first quarter worth about $123,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.